Skip to main content

Home/ Dr. Goodyear/ Group items tagged immunotherapy

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Nathan Goodyear

Cancer immunotherapy comes of age - 0 views

www.ncbi.nlm.nih.gov/...PMC3967235

cancer immunotherapy

shared by Nathan Goodyear on 11 Jan 19 - No Cached
  • Nathan Goodyear on 11 Jan 19
     
    another nice review of immunotherapy in cancer; though the use of immunotherapy is becoming blurry based on who is using the term.
Nathan Goodyear

Immunotherapy targets metastatic breast cancer-cell mutations - National Cancer Institute - 0 views

www.cancer.gov/...gets-breast-cancer-case-report

immunotherapy cancer tumor-infiltrating lymphocytes TILs

shared by Nathan Goodyear on 08 Jun 18 - No Cached
  • Nathan Goodyear on 08 Jun 18
     
    This is simply a press release from the NCI, but it highlights the move to immunotherapy as the future of cancer therapy.
Nathan Goodyear

Oncolytic viruses as engineering platforms for combination immunotherapy | Nature Revie... - 0 views

www.nature.com/...s41568-018-0009-4

RIGIVIR cancer immunotherapy oncolytic therapy

shared by Nathan Goodyear on 23 Oct 18 - No Cached
  • Nathan Goodyear on 23 Oct 18
     
    Only abstract available here, but good opinion piece on the future, here and now, in the field of immunotherapy in the treatment of cancer-oncolytic virus. Of course, they focus on the genetic altered virus', yet an unaltered enterovirus currently exists on the market.
Nathan Goodyear

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Com... - 0 views

www.ncbi.nlm.nih.gov/...PMC5572324

cancer PD-1 PDL-1 immune system immunotherapy

shared by Nathan Goodyear on 25 Sep 18 - No Cached
  • Nathan Goodyear on 25 Sep 18
     
    Good review of PD-1 and PDL-1 siganling in the immune system in cancer immunotherapy.
Nathan Goodyear

Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead - 0 views

jcmtjournal.com/...2275

cancer immunotherapy

shared by Nathan Goodyear on 11 Jan 19 - No Cached
  • Nathan Goodyear on 11 Jan 19
     
    great review of the history of immunotherapy in cancer treatment
Nathan Goodyear

A CLINICAL-STUDY OF IMMUNOTHERAPY VERSUS ENDOCRINE THERAPY VERSUS CHEMOTHERAPY IN THE T... - 0 views

www.spandidos-publications.com/...1277

cancer IL-2 melatonin pancreatic cancer

shared by Nathan Goodyear on 10 May 18 - No Cached
  • Nathan Goodyear on 10 May 18
     
    Head to head study of IL-2 + melatonin versus chemotherapy in advanced pancreatic cancer found slightly better outcomes in the immunotherapy arm versus standard chemotherapy.  This difference was statistically significant.
Nathan Goodyear

High-dose vitamin C enhances cancer immunotherapy - 0 views

sci.bban.top/...scitranslmed.aay8707.pdf

"Vitamin C" "IV vitamin cancer immunotherapy immune system

shared by Nathan Goodyear on 02 Apr 21 - No Cached
  • Nathan Goodyear on 02 Apr 21
     
    Absolute must read. IVC augments immune system and immunotherapy.
Nathan Goodyear

Impact of acetaminophen on the efficacy of immunotherapy in cancer patients - Annals of... - 0 views

www.annalsofoncology.org/...fulltext

cancer immunotherapy Tylenol acetominophen

shared by Nathan Goodyear on 01 Aug 23 - No Cached
  • Nathan Goodyear on 01 Aug 23
     
    Tylenol blunts immunotherapy treatment efficacy.
Nathan Goodyear

The role of opioids in cancer response to immunotherapy | Journal of Translational Medi... - 0 views

translational-medicine.biomedcentral.com/...s12967-021-02784-8

immunotherapy immunosuppression morphine Opiates immun

shared by Nathan Goodyear on 13 Nov 22 - No Cached
  • Nathan Goodyear on 13 Nov 22
     
    opioids use during immunotherapy is associated with early progression, potentially representing a predictive factor for PFS and negatively influencing OS as well.
Nathan Goodyear

Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in ... - 0 views

www.ncbi.nlm.nih.gov/...PMC4560272

RIGVIR cancer oncolytic therapy immunotherapy cancer immunotherapy

shared by Nathan Goodyear on 16 Oct 18 - No Cached
  • Rigvir is a 2 ml frozen solution
  • ECHO-7 virus strain, Picornaviridae family, Enterovirus genus, Enteric Cytopathic Human Orphan (ECHO) type 7, group IV, positive-sense single-stranded RNA virus
  • a few side effects were reported, for example subfebrile temperature (37.5°C for a couple of days), pain in the tumour area, sleepiness and diarrhoea
  • ...12 more annotations...
  • In this retrospective study, however, there was no record of any untoward side effect from Rigvir treatment or its discontinuation
  • Early observations of tumour regressions after virus infections have been published starting from the late 19th century
  • The present results show that in substage IB, IIA, IIB and IIC melanoma patients, Rigvir administration after surgery significantly (P<0.05) prolongs survival compared with patients who were managed according to current published guidelines
  • no value higher than grade 2 was recorded in Rigvir-treated patients. This is in contrast to most other cancer therapies, where grades 3 and 4 are frequently observed
  • Administration of virus induces the formation of neutralising antibodies that might potentially influence the efficiency of Rigvir
  • In 94 healthy adult participants tested, the titres were found to be low (1 : 20 to 1 : 62) 39,40. When tested in 155 adult cancer patients who had not been treated with Rigvir, neutralising antibodies against ECHO-7 were detected in ∼50% of the patients
  • the presence of ECHO-7 antibodies was shown to increase with age in children and level off to a plateau of around 75% in adults
  • Rigvir is an immunomodulator that affects both the humoral, antibody-mediated, and the cellular immune systems
  • neutralising antibodies do not affect efficacy when local or regional administration is used
  • it reduces the viability of melanoma, as well as pulmonary, gastric, pancreatic, bone, and breast cancer cell cultures
  • It is oncolytic in melanoma and rectum cancer patients
  • shown to improve the 5-year survival in rectum cancer patients
  • Nathan Goodyear on 16 Oct 18
     
    RIGVIR shown to improve survival against standard therapy in stage IB, IIA, IIB, and IIC in malignant melanoma patients in retrospective study. Side effects are minimal. Neutralizing antibodies are an area to watch that likely effects individual outcome beyond that of the type of cancer
Nathan Goodyear

Approved Drugs > Modification of the Dosage Regimen for Nivolumab - 0 views

www.fda.gov/...ucm520871.htm

immunotherapy cancer nivolumab monoclonal antibodies

shared by Nathan Goodyear on 13 Jul 18 - No Cached
  • Nathan Goodyear on 13 Jul 18
     
    FDA recommends nivolumab, PD-1 inhibitor immunotherapy, at 240 mg IV Q2 weeks.
Nathan Goodyear

Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment ... - 0 views

www.ncbi.nlm.nih.gov/...PMC5382272

cancer PD-1 immunotherapy programmed death-1

shared by Nathan Goodyear on 20 Apr 18 - No Cached
  • Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), the first immune checkpoint receptor to be clinically targeted, is exclusively expressed on the surface of CD4+ and CD8+ T cells in lymphatic tissue and is involved in T-cell regulation, proliferation, and tolerance
  • programmed death-1 (PD-1) immune checkpoint inhibitor antibodies, which restores T-cell effector function and augments the host anti-tumor response by blocking the binding of either programmed death-ligand 1 (PD-L1) and/or PD-L2 to PD-1 receptors
  • lung cancer is the first and second cause of cancer mortality in men and women
  • ...1 more annotation...
  • Eighty-five percent of lung cancers are non-small-cell lung cancer (NSCLC)
  • Nathan Goodyear on 20 Apr 18
     
    To read update article on PD-1 and immunotherapy.
Nathan Goodyear

Adjuvant histamine in cancer immunotherapy, Seminars in Cancer Biology | 10.1006/scbi.2... - 0 views

www.deepdyve.com/...ancer-immunotherapy-6XEaCggcvx

histamine IL-2 NK NK cells immunotherapy cancer

shared by Nathan Goodyear on 12 May 18 - No Cached
  • Nathan Goodyear on 12 May 18
     
    histamine dihydrochloride augments IL-2 stimulation of NK and blocks the monocyte/macrophage inhibition of IL-2 stimulation of NK cells.
Nathan Goodyear

A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal ... - 0 views

www.ncbi.nlm.nih.gov/...10928160

melatonin IL-2 immunotherapy cancer multiple myeloma leukemia Hodgkin's disease

shared by Nathan Goodyear on 10 May 18 - No Cached
  • Nathan Goodyear on 10 May 18
     
    Abstract only here.  Immunotherapy of IL-2 + melatonin provided lack of progression of 67% of patients included with a average duration of 21+ months in patients with untreatable advanced hematologic cancer.  Again, no toxicities.  Interesting, the survival time was similar to the previously reported survival times with the highly toxic high dose IL-2 therapy.
Nathan Goodyear

Phase II Randomized Trial of Autologous Formalin-Fixed Tumor Vaccine for Postsurgical R... - 0 views

clincancerres.aacrjournals.org/...1574

immunotherapy cancer hepatocellular cancer liver cancer

shared by Nathan Goodyear on 24 May 18 - No Cached
  • Nathan Goodyear on 24 May 18
     
    Specific immunotherapy from patient the specific antigens of cancer cells fixed in formalin improves survival in hepatocellular cancer.
Nathan Goodyear

Cytokine release syndrome | Journal for ImmunoTherapy of Cancer | Full Text - 0 views

jitc.biomedcentral.com/...s40425-018-0343-9

immune system cytokine release syndrome cancer CRS

shared by Nathan Goodyear on 01 Apr 20 - No Cached
  • Nathan Goodyear on 01 Apr 20
     
    Good review of the immunotherapy induced risk of CRS, including a good discussion of the pathogenesis.
Nathan Goodyear

Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving A... - 0 views

www.sciencedirect.com/...S0302283820305431

gut microbiota gut microbiome gut flora akkermansia muciniphila cancer immunotherapy

shared by Nathan Goodyear on 22 Apr 21 - No Cached
  • Nathan Goodyear on 22 Apr 21
     
    Gut microbiome diversity associated with increase in immunotherapy efficacy; particularly akermansia
Nathan Goodyear

Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patie... - 0 views

science.sciencemag.org/...595

immunotherapy gut bacteria melanoma cancer PD-1 gut flora gut microbiota gut microbiome

shared by Nathan Goodyear on 07 Feb 21 - No Cached
  • Nathan Goodyear on 07 Feb 21
     
    Fecal transplant study. Gut microbes improve efficacy of anti-PD-1 therapy immunotherapy.
Nathan Goodyear

Effects of Hyperthermia on the Host Immune System : From NK Cell-based Science to Clini... - 0 views

www.jstage.jst.go.jp/...en

NK cells hyperthermia immunotherapy

shared by Nathan Goodyear on 19 Feb 21 - No Cached
  • Nathan Goodyear on 19 Feb 21
     
    Immunotherapy augments internal NK cells and NK cell therapy.
Nathan Goodyear

Combining surgery and immunotherapy: turning an immunosuppressive effect into a therape... - 0 views

jitc.biomedcentral.com/...s40425-018-0398-7

surgery cancer immunotherapy immunosuppression metastasis

shared by Nathan Goodyear on 20 Feb 21 - No Cached
Amol kashikar liked it
  • Nathan Goodyear on 20 Feb 21
     
    The post-operative time period is critical to the long-term metastatic risk of cancer because surgery suppresses the immune system in this critical post-operative time period.
1 - 20 of 231 Next › Last »
Showing 20▼ items per page